Monitor the full ASCO poster on May 30 for additional efficacy details and dose expansion data. Positive early signals could support partnership interest or pipeline valuation, but the small sample size warrants caution until larger cohorts confirm.
Price Chart
Executive Summary
Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability, target engagement, and early anti-tumor activity (3 partial responses in 19 evaluable patients) in heavily pretreated advanced solid tumors. The data will be presented at ASCO 2026 on May 30. This early clinical signal supports continued development but remains preliminary.
Key Facts
- No dose-limiting toxicities observed up to 45 mg daily; no treatment discontinuations due to TRAEs.
- Among 19 evaluable patients, tumor shrinkage in 13, with 2 confirmed and 1 unconfirmed partial response.
- OP-3136 demonstrated sustained reduction in H3K23 acetylation, confirming on-target KAT6 inhibition.
- Data to be presented at ASCO 2026 (May 30) and Phase 1 dose expansion ongoing.
- The company also will present a trial-in-progress for Phase 3 OPERA-02 (palazestrant + ribociclib) at ASCO.
Financial Impact
No financial figures disclosed; early clinical data may increase probability of success for OP-3136 pipeline value.
Risk Factors
- Phase 1 data is preliminary with small sample size (19 evaluable); response rates may not be durable or reproducible in larger groups.
- Common grade 3 TRAEs (anemia 6%, neutropenia 28%) may limit tolerability at higher doses or in combination.
- No control arm; efficacy signals need confirmation in randomized expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-234848 |
| Document: olma-ex99_1.htm | 0001193125-26-234848 |
| Document: 0001193125-26-234848-index-headers.html | 0001193125-26-234848 |
| Document: 0001193125-26-234848-index.html | 0001193125-26-234848 |
| Document: 0001193125-26-234848.txt | 0001193125-26-234848 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.23 (+31.11%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.23 (−42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access